Measurement of Sputum Mycobacterium tuberculosis Messenger RNA as a Surrogate for Response to Chemotherapy
- 1 July 1999
- journal article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 160 (1) , 203-210
- https://doi.org/10.1164/ajrccm.160.1.9811006
Abstract
Effective treatment regimens for pulmonary tuberculosis are difficult to assess because of the slow growth rate of Mycobacterium tuberculosis in culture and its protracted clearance from sputum. A rapid method that reflects effective antimicrobial activity would markedly advance evaluation of treatment and promote the assessment of new antituberculosis drugs. Conventional methods measure the progressive reduction of numbers of acid-fast bacilli in the sputum smear and the clearance of organisms in sputum culture. In this study, we measured levels of M. tuberculosis 85B (alpha antigen) messenger RNA (mRNA), 16S ribosomal RNA (rRNA), and IS6110 DNA in patients' sputa to ascertain whether they could serve as potential surrogate markers of response to chemotherapy. Sputum specimens were sequentially collected for up to a year from 19 smear-positive pulmonary tuberculosis patients receiving an optimal drug treatment regimen. Nucleic acids were isolated from these specimens, and two M. tuberculosis molecular targets (mRNA, DNA) were quantified, using the ABI Prism 7700 Sequence Detection System. The Mycobacterium genus-specific 16S rRNA was quantified with a limiting dilution RT-PCR assay. Results show that levels of 85B mRNA declined after initiation of therapy, as did viable M. tuberculosis colony counts, with 90% of patients becoming negative for both markers after 2 mo of treatment. The rapid disappearance of M. tuberculosis mRNA from sputum suggests that it is a good indicator of microbial viability and a useful marker for rapid assessment of response to chemotherapy.Keywords
This publication has 39 references indexed in Scilit:
- Time to Detection of Mycobacterium Tuberculosis in Sputum Culture Correlates With Outcome in Patients Receiving Treatment for Pulmonary TuberculosisChest, 1998
- Early Bactericidal Activity of Isoniazid in Pulmonary TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 1997
- The Early Bactericidal Activity of Isoniazid Related to Its Dose Size in Pulmonary TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 1997
- Early Bactericidal and Sterilizing Activities of Ciprofloxacin in Pulmonary TuberculosisAmerican Review of Respiratory Disease, 1993
- Assessment of New Sterilizing Drugs for Treating Pulmonary Tuberculosis by Culture at 2 MonthsAmerican Review of Respiratory Disease, 1993
- Tuberculosis control in BangladeshThe Lancet, 1992
- The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosisTubercle and Lung Disease, 1992
- USPHS Tuberculosis Short-Course Chemotherapy Trial 21: Effectiveness, Toxicity, and AcceptabilityAnnals of Internal Medicine, 1990
- A Controlled Trial of 3-Month, 4-Month, and 6-Month Regimens of Chemotherapy for Sputum-smear-negative Pulmonary Tuberculosis: Results at 5 YearsAmerican Review of Respiratory Disease, 1989
- Patient Compliance: The Most Serious Remaining Problem in the Control of Tuberculosis in the United StatesChest, 1979